Subtopic Deep Dive
Pim-2 Kinase in Hematological Malignancies
Research Guide
What is Pim-2 Kinase in Hematological Malignancies?
Pim-2 kinase is a serine/threonine kinase overexpressed in hematological malignancies that promotes cancer cell survival by phosphorylating anti-apoptotic proteins and enhancing cytokine signaling.
Pim-2 kinase contributes to leukemia and lymphoma pathogenesis through JAK/STAT pathway activation and resistance to apoptosis. Elevated PIM2 levels occur in blood cancers, correlating with poor prognosis (Brault et al., 2010, 363 citations). Research spans 10+ papers linking Pim kinases to hematologic malignancy therapy.
Why It Matters
Pim-2 sustains malignant cell survival in hematological cancers, driving chemotherapy resistance via BAD phosphorylation and IL-6/JAK2/STAT3 signaling (Amaravadi, 2005; Huang et al., 2022). Targeting Pim kinases offers therapeutic potential in lymphomas where PIM1/PIM2 cooperate with MYC oncogenes (Brault et al., 2010). STAT3 inhibitors disrupt Pim-2-related pathways in leukemia, improving outcomes in preclinical models (Siveen et al., 2014).
Key Research Challenges
Developing Selective Pim-2 Inhibitors
Pim-2 shares high homology with Pim-1, complicating selective inhibition without off-target effects on normal hematopoiesis (Brault et al., 2010). Clinical translation fails due to kinase redundancy in blood cancers. Amaravadi (2005) notes overlapping Akt/Pim substrates hinder specificity.
Overcoming Chemotherapy Resistance
Pim-2 phosphorylates substrates evading apoptosis, sustaining leukemia cells post-treatment (Amaravadi, 2005). STAT3 activation via IL-6/JAK2 upregulates Pim-2 in resistant lymphomas (Huang et al., 2022). Combination therapies require biomarker validation.
Identifying Prognostic Biomarkers
PIM2 expression correlates variably with survival across leukemia subtypes, needing standardized assays (Brault et al., 2010). STAT3/Pim crosstalk complicates prognostic models (Siveen et al., 2014). Large cohort studies lack integration with kinase activity metrics.
Essential Papers
Targeting PI3K in cancer: mechanisms and advances in clinical trials
Jing Yang, Ji Nie, Xuelei Ma et al. · 2019 · Molecular Cancer · 1.5K citations
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Lei Zhong, Yueshan Li, Liang Xiong et al. · 2021 · Signal Transduction and Targeted Therapy · 1.5K citations
Abstract Due to the advantages in efficacy and safety compared with traditional chemotherapy drugs, targeted therapeutic drugs have become mainstream cancer treatments. Since the first tyrosine kin...
Targeting the STAT3 signaling pathway in cancer: Role of synthetic and natural inhibitors
Kodappully Sivaraman Siveen, Sakshi Sikka, Rohit Surana et al. · 2014 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 628 citations
The survival kinases Akt and Pim as potential pharmacological targets
Ravi K. Amaravadi · 2005 · Journal of Clinical Investigation · 401 citations
The Akt and Pim kinases are cytoplasmic serine/threonine kinases that control programmed cell death by phosphorylating substrates that regulate both apoptosis and cellular metabolism. The PI3K-depe...
Role of STAT3 in Cancer Metastasis and Translational Advances
Mohammad Zahid Kamran, Prachi Patil, Rajiv P. Gude · 2013 · BioMed Research International · 391 citations
Signal transducer and activator of transcription 3 (STAT3) is a latent cytoplasmic transcription factor, originally discovered as a transducer of signal from cell surface receptors to the nucleus. ...
The role of IL-6/JAK2/STAT3 signaling pathway in cancers
Bei Huang, Xiaoling Lang, Xihong Li · 2022 · Frontiers in Oncology · 380 citations
Interleukin-6 (IL-6) is a pleiotropic cytokine involved in immune regulation. It can activate janus kinase 2 (JAK2)-signal transducer and activator of transcription 3 (STAT3) signaling pathway. As ...
PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers
L. Brault, Christelle Gasser, Franz Bracher et al. · 2010 · Haematologica · 363 citations
The identification as cooperating targets of Proviral Integrations of Moloney virus in murine lymphomas suggested early on that PIM serine/threonine kinases play an important role in cancer biology...
Reading Guide
Foundational Papers
Start with Amaravadi (2005, 401 citations) for Pim kinase survival mechanisms and Brault et al. (2010, 363 citations) for hematologic malignancy specifics, as they establish core anti-apoptotic roles.
Recent Advances
Study Huang et al. (2022) on IL-6/JAK2/STAT3/Pim-2 in cancers and Yang et al. (2022) on PTK inhibitor resistance for latest therapeutic advances.
Core Methods
Core techniques include kinase activity assays, siRNA knockdown for Pim-2 validation, and JAK/STAT inhibitors like AZD1480 to disrupt signaling (Brault et al., 2010; Siveen et al., 2014).
How PapersFlow Helps You Research Pim-2 Kinase in Hematological Malignancies
Discover & Search
Research Agent uses searchPapers('Pim-2 kinase hematological malignancies') to retrieve Brault et al. (2010), then citationGraph to map 363 citing papers on Pim inhibitors in leukemia, and findSimilarPapers to uncover related STAT3/Pim studies like Huang et al. (2022). exaSearch expands to unpublished preprints on Pim-2 clinical trials.
Analyze & Verify
Analysis Agent applies readPaperContent on Brault et al. (2010) to extract Pim-2 expression data in lymphomas, verifyResponse with CoVe to cross-check claims against Amaravadi (2005), and runPythonAnalysis to plot kinase survival correlations from supplementary tables using pandas/matplotlib. GRADE grading scores evidence strength for therapeutic targeting.
Synthesize & Write
Synthesis Agent detects gaps in Pim-2/STAT3 inhibitor combinations via contradiction flagging across Siveen et al. (2014) and Huang et al. (2022), while Writing Agent uses latexEditText for manuscript sections, latexSyncCitations to integrate 10+ references, latexCompile for PDF output, and exportMermaid for JAK/STAT/Pim-2 pathway diagrams.
Use Cases
"Analyze Pim-2 expression correlations with survival in leukemia datasets from recent papers"
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas correlation heatmap on Brault et al. 2010 data) → matplotlib survival plot output.
"Draft LaTeX review on Pim-2 inhibitors for lymphoma therapy"
Synthesis Agent → gap detection → Writing Agent → latexEditText (intro/methods) → latexSyncCitations (Brault 2010, Amaravadi 2005) → latexCompile → PDF with pathway figure.
"Find GitHub repos implementing Pim kinase inhibitor screening models"
Research Agent → paperExtractUrls (Amaravadi 2005) → paperFindGithubRepo → githubRepoInspect → code for Pim-2 docking simulations.
Automated Workflows
Deep Research workflow conducts systematic review: searchPapers(50+ on Pim-2 malignancies) → citationGraph → structured report with GRADE scores on Brault et al. (2010). DeepScan applies 7-step analysis: readPaperContent → CoVe verify → runPythonAnalysis on STAT3/Pim data from Huang et al. (2022). Theorizer generates hypotheses on Pim-2/JAK2 combinations from Siveen et al. (2014).
Frequently Asked Questions
What defines Pim-2 kinase's role in hematological malignancies?
Pim-2 is a serine/threonine kinase activated by JAK/STAT signaling that phosphorylates BAD to block apoptosis in leukemia and lymphoma cells (Amaravadi, 2005; Brault et al., 2010).
What methods target Pim-2 in cancer therapy?
Small molecule inhibitors block Pim kinase activity; pan-Pim drugs combined with STAT3 inhibitors address redundancy in blood cancers (Brault et al., 2010; Siveen et al., 2014).
What are key papers on Pim-2 in hematologic cancers?
Brault et al. (2010, Haematologica, 363 citations) details PIM kinases in lymphomas; Amaravadi (2005, 401 citations) covers Pim/Akt survival roles.
What open problems exist in Pim-2 research?
Selective Pim-2 inhibitors elude development due to family homology; prognostic PIM2 biomarkers need validation in large leukemia cohorts (Brault et al., 2010).
Research Cancer Mechanisms and Therapy with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Pim-2 Kinase in Hematological Malignancies with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Cancer Mechanisms and Therapy Research Guide